Register      Login
Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
RESEARCH ARTICLE

A national study of the clinical management of HIV-positive women in Australia: what are the successes and where are the gaps?

Michelle L. Giles A B U , Aleece MacPhail A , Charlotte Bell C , Catriona S. Bradshaw D E , Virginia Furner F , Manoji Gunathilake G H , Mina John I , Sushena Krishnaswamy J K , Sarah J. Martin L M , Catriona Ooi N , Louise Owen O , Darren Russell P Q , Alan Street R and Jeffrey J. Post F S T
+ Author Affiliations
- Author Affiliations

A Department of Infectious Diseases, Alfred Health, 55 Commercial Road, Melbourne, Vic. 3004, Australia.

B Department of Obstetrics and Gynecology, Monash University, 246 Clayton Road, Clayton, Vic. 3168, Australia.

C Royal Adelaide Hospital, Port Road, Adelaide, SA 5000, Australia.

D Melbourne Sexual Health Centre, 580 Swanston Street, Carlton, Vic. 3053, Australia.

E Central Clinical School, Alfred Centre, 99 Commercial Road, Melbourne, Vic. 3004 , Australia.

F The Albion Centre, 150–154 Albion Street, Surry Hills, NSW 2010, Australia.

G Sexual Health and Blood Borne Virus Unit, Centre for Disease Control, Northern Territory Department of Health, PO Box 40596, Casuarina, NT 0811, Australia.

H Kirby Institute, University of New South Wales, Level 6, Wallace Wurth Building, High Street, Kensington, NSW 2052, Australia.

I Department of Clinical Immunology, Royal Perth Hospital, Wellington Street, Perth, WA 6000, Australia.

J Department of Medicine, Alice Springs Hospital, 6 Gap Road, The Gap, NT 0870, Australia.

K Monash Infectious Diseases, Monash Health, 246 Clayton Road, Clayton, Vic. 3168, Australia.

L Canberra Sexual Health Centre, Building 5, Canberra Hospital, Hospital Road, Garran, ACT 2605, Australia.

M Australian National University Medical School, Building 4, Canberra Hospital, Hospital Road, Garran, ACT 2605, Australia.

N Western Sydney Sexual Health Centre, 162 Marsden Street, Parramatta, NSW 2150, Australia.

O Statewide Sexual Health Service, Clinic 60, 60 Collins Street, Hobart, Tas. 7000 , Australia.

P Cairns Sexual Health Service, 381 Sheridan Street, Cairns North, Qld 4870, Australia.

Q School of Medicine and Dentistry, James Cook University, 1/14-88 McGregor Road, Smithfield, Qld 4878, Australia.

R Victorian Infectious Diseases Service, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Parkville, Vic. 3000, Australia.

S Department of Infectious Diseases, Prince of Wales Hospital, Barker Street, Randwick, NSW 2031, Australia.

T Prince of Wales Clinical School, University of New South Wales, Sydney, NSW 2052, Australia.

U Corresponding author. Email: m.giles@alfred.org.au

Sexual Health 16(3) 282-288 https://doi.org/10.1071/SH18070
Submitted: 6 April 2018  Accepted: 23 February 2019   Published: 6 June 2019

Abstract

Background: Women comprise ~10% of people living with HIV in Australia, so are often underrepresented in research. Methods: This study invited clinicians providing care to women living with HIV to complete an anonymous survey containing questions related to four key areas: HIV (including diagnosis, treatment and virological outcomes), reproductive health (including sexual activity, contraception, pregnancy and outcomes) and linkage and retention in care. Results: In total, 484 surveys were received, with responses from all states and territories. Most women living with HIV in Australia are on treatment (>90%) and virologically suppressed (>90% have a viral load <50 copies mL−1). Almost 75% of women have had at least one switch in treatment (with toxicity almost as common as simplification as the indication). Treatment interruption is also relatively common, but is more likely the longer a woman has been diagnosed, if she is on benefits (P = 0.007) and is the primary carer of children without a partner (P = 0.001). In Australia, women living with HIV are a diverse heterogeneous group, with over 70 different countries of birth and almost half speaking a language other than English at home. Mental health diagnosis was the most common co-morbid condition identified. A total of 21% of women were post-menopausal, with 42% reporting symptoms to their healthcare provider, but only 17% were receiving treatment for symptoms attributed to menopause. Conclusions: As well as strategies to support women vulnerable to treatment interruption, important areas for future investment in research and clinical care include co-morbid mental health and menopause symptoms and treatment.

Additional keywords: antiretroviral treatment, interruption, menopause, reproductive health, switching.


References

[1]  The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2017. Sydney: Kirby Institute, UNSW Sydney; 2017.

[2]  Curno MJ, Rossi S, Hodges-Mameletzis I, Johnston R, Price MA, Heidari S. A systematic review of the inclusion (or exclusion) of women in HIV research: from clinical studies of antiretrovirals and vaccines to cure strategies. J Acquir Immune Defic Syndr 2016; 71 181–8.
A systematic review of the inclusion (or exclusion) of women in HIV research: from clinical studies of antiretrovirals and vaccines to cure strategies.Crossref | GoogleScholarGoogle Scholar | 26361171PubMed |

[3]  The Kirby Institute. Australian HIV Observational Database Annual Report 2017. NSW. Vol 17, Number 1: Sept 2017. Sydney: The Kirby Institute, UNSW Australia; 2017.

[4]  Thorpe R, Power J, Brown G, Lyons A, Dowsett GW, Lucke J. HIV Futures 8: women living with HIV in Australia. Melbourne: The Australian Research Centre in Sex, Health and Society, La Trobe University; 2017.

[5]  Kay ES, Batey DS, Mugavero MJ. The HIV treatment cascade and care continuum: updates, goals and recommendations for the future. AIDS Res Ther 2016; 13 35
The HIV treatment cascade and care continuum: updates, goals and recommendations for the future.Crossref | GoogleScholarGoogle Scholar | 27826353PubMed |

[6]  Medland NA, Chow EPF, McMahon JW, Elliott JH, Hoy JF, Fairley CK. Time from HIV diagnosis to commencement of antiretroviral therapy as an indicator to supplement the HIV cascade: dramatic fall from 2011 to 2015. PLoS One 2017; 12 e0177634
Time from HIV diagnosis to commencement of antiretroviral therapy as an indicator to supplement the HIV cascade: dramatic fall from 2011 to 2015.Crossref | GoogleScholarGoogle Scholar | 28520807PubMed |

[7]  Lee MP, Zhou J, Messerschmidt L, Honda M, Ditangco R, Sirisanthana T, Kumarasamy N, Phanuphak P, Chen Y-MA, Zhang F, Saphonn V, Kiertiburanakul S, Lee CKC, Pujari S, Choi JY, Kamarulzaman A, Yunihastuti E, Merati TP, Lim P-L, Li PCK, on behalf of the TREAT Asia HIV Observational Database. Impact of gender on long-term treatment outcomes of highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database. AIDS Patient Care STDS 2015; 29 229–31.
Impact of gender on long-term treatment outcomes of highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database.Crossref | GoogleScholarGoogle Scholar | 25774867PubMed |

[8]  Currier J, Averitt Bridge D, Hagins D, Zorrilla CD, Feinberg J, Ryan R, Falcon R, Tennenberg A, Mrus J, Squires K, on behalf of the GRACE (Gender, Race, And Clinical Experience) Study Group. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial Ann Intern Med 2010; 153 349–57.
Sex-based outcomes of darunavir-ritonavir therapy: a single-group trialCrossref | GoogleScholarGoogle Scholar | 20855799PubMed |

[9]  Mazhude C, Jones S, Murad S, Taylor C, Easterbrook PJ. Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash. AIDS 2002; 16 1566–8.
Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash.Crossref | GoogleScholarGoogle Scholar | 12131201PubMed |

[10]  Gandhi M, Aweeka F, Greenblatt R, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 2004; 44 499–523.
Sex differences in pharmacokinetics and pharmacodynamics.Crossref | GoogleScholarGoogle Scholar | 14744256PubMed |

[11]  Giles ML, Achhra A, Abraham AG, Haas AD, Gill MJ, Lee MP, Luque M, McGowan C, Cornell M, Braitstein P, de Rekeneire N, Becquet R, Wools-Kaloustian K, Law M. Sex-based differences in antiretroviral therapy initiation, switching and treatment interruptions: a global overview from the International Epidemiological Databases to Evaluate AIDS (IeDEA). J Int AIDS Soc 2018; 21 e25149
Sex-based differences in antiretroviral therapy initiation, switching and treatment interruptions: a global overview from the International Epidemiological Databases to Evaluate AIDS (IeDEA).Crossref | GoogleScholarGoogle Scholar | 29956882PubMed |

[12]  Australian Bureau of Statistics. National Health Survey: First Results, 2014–15. Canberra: Australian Government; 2016.

[13]  Robertson K, Bayon C, Molina JM, McNamara P, Resch C, Muñoz-Moreno JA, Kulasegaram R, Schewe K, Burgos-Ramirez A, De Alvaro C, Cabrero E, Guion M, Norton M, van Wyk J. Screening for neurocognitive impairment, depression and anxiety in HIV-infected patients in Western Europe and Canada. AIDS Care 2014; 26 1555–61.
Screening for neurocognitive impairment, depression and anxiety in HIV-infected patients in Western Europe and Canada.Crossref | GoogleScholarGoogle Scholar | 25029599PubMed |

[14]  Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Asboe D, Viciana P, Gutiérrez F, Clotet B, Pradier C, Gerstoft J, Weber R, Westling K, Wandeler G, Prins JM, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA 2016; 316 171–81.
Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar | 27404185PubMed |

[15]  The Joint United Nations Programme on HIV and AIDS (UNAIDS). 90–90–90 – an ambitious treatment target to help end the AIDS epidemic. Geneva: UNAIDS; 2017. Available online at: http://www.unaids.org/en/resources/documents/2017/90-90-90 [verified 17 May 2019].